

AD-A191 772


HYALURONIDASE: PURIFICATION AND INHIBITION BY A GOLD
COMPLEX AND A STEROID DERIVATIVE(U) AUBURN UNIV AL
G G DURANTE 11 DEC 87 N00220-85-G-3212

1/1

UNCLASSIFIED

F/G 6/1

NL



LT. GARY DURANTE , 116-52-3745

AUBURN UNIVERSITY

MASTERS THESIS IN CHEMISTRY

HYALURONIDASE: PURIFICATION AND INHIBITION BY
A GOLD COMPLEX AND A STEROID DERIVATIVE

Gary Gerard Durante

N00228-85-6 3212

DTIC
ELECTE
APR 14 1988
S D E

Certificate of Approval:

John L. Aull

John L. Aull
Professor, Chemistry

Michael E. Friedman

Michael E. Friedman, Chairman
Professor, Chemistry

Philip B. Shevlin

Philip Shevlin
Professor, Chemistry

Dana M. Vaughn

Dana M. Vaughn, Assistant
Professor, Biochemistry

J. Howard Hargis

J. Howard Hargis
Professor, Chemistry

Norman J. Doorenbos

Norman J. Doorenbos, Dean
Graduate School

This document has been approved
for public release and sale; its
distribution is unlimited.

88 4 13 036

HYALURONIDASE: PURIFICATION AND INHIBITION BY A
GOLD COMPLEX AND A STEROID DERIVATIVE

Gary Gerard Durante

A Thesis
Submitted to
the Graduate Faculty of
Auburn University
in Partial Fulfillment of the
Requirements for the
Degree of
Master of Science

Auburn, Alabama
December 11, 1987

HYALURONIDASE: PURIFICATION AND INHIBITION BY
A GOLD COMPLEX AND A STEROID DERIVATIVE

Gary Gerard Durante

Permission is granted to Auburn University to make copies of this thesis at its discretion, upon the request of individuals or institutions and at their expense. The author reserves all publication rights.

Gary Gerard Durante
Signature of Author

September 9, 1987
Date

Copy sent to:

Name

Date

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By <u>Pa Sam 50</u>	
Distribution	
Availability Codes	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	
146	
147	
148	
149	
150	
151	
152	
153	
154	
155	
156	
157	
158	
159	
160	
161	
162	
163	
164	
165	
166	
167	
168	
169	
170	
171	
172	
173	
174	
175	
176	
177	
178	
179	
180	
181	
182	
183	
184	
185	
186	
187	
188	
189	
190	
191	
192	
193	
194	
195	
196	
197	
198	
199	
200	
201	
202	
203	
204	
205	
206	
207	
208	
209	
210	
211	
212	
213	
214	
215	
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	
230	
231	
232	
233	
234	
235	
236	
237	
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	
251	
252	
253	
254	
255	
256	
257	
258	
259	
260	
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	
271	
272	
273	
274	
275	
276	
277	
278	
279	
280	
281	
282	
283	
284	
285	
286	
287	
288	
289	
290	
291	
292	
293	
294	
295	
296	
297	
298	
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	
318	
319	
320	
321	
322	
323	
324	
325	
326	
327	
328	
329	
330	
331	
332	
333	
334	
335	
336	
337	
338	
339	
340	
341	
342	
343	
344	
345	
346	
347	
348	
349	
350	
351	
352	
353	
354	
355	
356	
357	
358	
359	
360	
361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	
387	
388	
389	
390	
391	
392	
393	
394	
395	
396	
397	
398	
399	
400	
401	
402	
403	
404	
405	
406	
407	
408	
409	
410	
411	
412	
413	
414	
415	
416	
417	
418	
419	
420	
421	
422	
423	
424	
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	
447	
448	
449	
450	
451	
452	
453	
454	
455	
456	
457	
458	
459	
460	
461	
462	
463	
464	
465	
466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	
477	
478	
479	
480	
481	
482	
483	
484	
485	
486	
487	
488	
489	
490	
491	
492	
493	
494	
495	
496	
497	
498	
499	
500	
501	
502	
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	
522	
523	
524	
525	
526	
527	
528	
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	
550	
551	
552	
553	
554	
555	
556	
557	
558	
559	
560	
561	
562	
563	
564	
565	
566	
567	
568	
569	
570	
571	
572	
573	
574	
575	
576	
577	
578	
579	
580	
581	
582	
583	
584	
585	
586	
587	
588	
589	
590	
591	
592	
593	
594	
595	
596	
597	
598	
599	
600	
601	
602	
603	
604	
605	
606	
607	
608	
609	
610	
611	
612	
613	
614	
615	
616	
617	
618	
619	
620	
621	
622	
623	
624	
625	
626	
627	
628	
629	
630	
631	
632	
633	
634	
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	
647	
648	
649	
650	
651	
652	
653	
654	
655	
656	
657	
658	
659	
660	
661	
662	
663	
664	
665	
666	
667	
668	
669	
670	
671	
672	
673	
674	
675	
676	
677	
678	
679	
680	
681	
682	
683	
684	
685	
686	
687	
688	
689	
690	
691	
692	
693	
694	
695	
696	
697	
698	
699	
700	
701	
702	
703	
704	
705	
706	
707	
708	
709	
710	
711	
712	
713	
714	
715	
716	
717	
718	
719	
720	
721	
722	
723	
724	
725	
726	
727	
728	
729	
730	
731	
732	
733	
734	
735	
736	
737	
738	
739	
740	
741	
742	
743	
744	
745	
746	
747	
748	
749	
750	
751	
752	
753	
754	
755	
756	
757	
758	
759	
760	
761	
762	
763	
764	
765	
766	
767	
768	
769	
770	
771	
772	
773	
774	
775	
776	
777	
778	
779	
780	
781	
782	
783	
784	
785	
786	
787	
788	
789	
790	
791	
792	
793	
794	
795	
796	
797	
798	
799	
800	
801	
802	
803	
804	
805	
806	
807	
808	
809	
810	
811	
812	
813	
814	
815	
816	
817	
818	
819	
820	
821	
822	
823	
824	
825	
826	
827	
828	
829	
830	
831	
832	
833	
834	
835	
836	
837	
838	
839	
840	
841	
842	
843	
844	
845	
846	
847	
848	
849	
850	
851	
852	
853	
854	
855	
856	
857	
858	
859	
860	
861	
862	
863	
864	
865	
866	
867	
868	
869	
870	
871	
872	
873	
874	
875	
876	
877	
878	
879	
880	
881	
882	
883	
884	
885	
886	
887	
888	
889	

VITA

Gary G. Durante, Lieutenant U.S. Navy, son of Paul and Diane (Zakrewski), was born March 14, 1958, in New Hartford, New York. He attended Holy Trinity grammar school and graduated from Notre Dame High School, New Hartford, New York, in 1976. In August, 1976, he entered the Citadel, The Military College of South Carolina, and was awarded the degree of Bachelor of Science (Biology) and commissioned an Ensign in the U. S. Navy on May 17, 1980. In July, 1980, he commenced training to obtain qualifications for supervision of gas turbine propulsion plants and graduated from the Surface Warfare Officer School, Newport, Rhode Island, in November, 1980. He served one sea tour from December, 1980, until July, 1983, on the gas turbine powered destroyer USS O'Bannon (DD-987). From July, 1983, to August, 1985, he served a tour of duty as an instructor at the U. S. Navy Gas Turbine Engineering School in Newport, Rhode Island. In September, 1985, he commenced graduate studies under the Navy's Post Graduate Education Program. He married Pamela Marie, daughter of Thomas and Leota Fisher, in July, 1984.

THESIS ABSTRACT

HYALURONIDASE: PURIFICATION AND INHIBITION BY
A GOLD COMPLEX AND A STEROID DERIVATIVE

Gary Gerard Durante

Master of Science, December 11, 1987
(B.Sc., The Citadel, 1980)

71 Typed Pages

Directed by Michael E. Friedman

↓ The enzyme hyaluronidase from human synovial fluid was partially purified using gel-filtration and chromatography on a hydroxylapatite column. A 4.1⁴ fold purification of hyaluronidase having a specific activity of 1.1×10^4 ^{micro}mol/min/mg was obtained. The enzyme was inhibited by the gold complex Auranofin, and the steroid derivative, 22⁴-ketocholesterol oxime.

It was shown that the complexes differed in their ability to inhibit the enzyme. The rate constants and equilibrium inhibition constants were calculated. The K_I value for Auranofin was 8.78 mM and its rate constant was 0.049 min^{-1} . The K_I value for 22-ketocholesterol oxime was 11.86 mM. ↓ Kinetic analyses demonstrated an apparent uncompetitive inhibition by the steroid derivative 22-ketocholesterol oxime. The r

ACKNOWLEDGEMENTS

The author wishes to thank his wife for the love and encouragement which made the completion of this work possible.

TABLE OF CONTENTS

LIST OF TABLES	viii
LIST OF FIGURES	ix
LIST OF ABBREVIATIONS	xi
I. INTRODUCTION	1
II. EXPERIMENTAL	19
Materials	19
Apparatus	20
Sample Preparation	21
Hyaluronidase Activity	21
Protein Concentration and Specific Activity	22
Purification of Hyaluronidase	22
Sephadex G-75-120 Chromotography	23
Hydroxylapatite Chromotography	24
Gel Electrophoresis	24
Procedure for Preparing the Gels	26
Inhibition Studies	27
III. RESULTS	29
Enzyme Analysis of Synovial Fluid	29
Canine Synovial Fluid	32
Human Synovial Fluid.	32
Gel Electrophoresis	33
Enzyme Inhibition	36
IV. CONCLUSIONS	47
REFERENCES	53

LIST OF TABLES

1. Enzymes in Synovial Fluid of Patients with Rheumatoid Arthritis	4
2. Amino Acid Composition of Purified Bee Venom Hyaluronidase	9
3. Comparison of Mean Hyaluronidase Activities in Canines	32
4. Purification Procedure for Human Synovial Fluid Hyaluronidase	33

LIST OF FIGURES

1.	Action of Hyaluronidase on Different Substrates	7
2.	Scheme for the Mechanism of Total Degradation of Hyaluronate by Rheumatoid Synovial Fluid . . .	12
3.	Gold Complexes Used in the Treatment of Rheumatoid Arthritis	18
4.	Standard Curve of Absorbance Versus Concentration of Acetylglucosamine	30
5.	Standard Curve of Absorbance Versus Concentration of Bovine Serum Albumin	31
6.	Chromotography of Human Synovial Fluid Hyaluronidase on Sephadex G-75-120 Column	34
7.	Chromatography of Human Synovial Fluid Hyaluronidase on Hydroxylapatite	35
8.	Protein Staining of the Gel Electrophoresis for Human Versus Canine Synovial Fluid	37
9.	Protein Identification Bands of Hyaluronidase Purification with Protein Standards	38
10.	Time Course Inactivation of Hyaluronidase by Auranofin	39
11.	Semilog Plot of Data From Figure 10 Against Inactivation Time by Auranofin	40
12.	Reciprocal Plot of Pseudo First Order Rate Constant with the Auranofin Concentration	41
13.	Time Course Inactivation of Hyaluronidase by 22-Ketocholesterol Oxime	42
14.	Semi-log Plot of Data From Figure 13 Against Inactivation Time by 22-Ketocholesterol Oxime. . .	43
15.	Lineweaver-Burk Plot of the Inhibition of Hyaluronidase by 22-Ketocholesterol Oxime	44

16. Secondary Plot Computed from the Lineweaver-Burk
Curves in Figure 15 46

LIST OF ABBREVIATIONS

A	absorbance
Auranofin	S-2,3,4,6-tetraacetyl-1- β -D-thiogluco- (triethylphosphine) gold (I)
BSA	Bovine Serum Albumin
cm	centimeter
EDTA	ethylenediaminetetraacetate
gm	gram
h	hour
Km	Michaelis constant
l	liter
ma	milliamperes
mg	milligram
min	minute
ml	milliliter
mM	millimolar
nm	nanometer
t	time
TCA	trichloroacetic acid
TEMED	N,N,N',N'-tetramethylethylenediamine
v	velocity
v/v	volume per volume
μ M	micromolar
μ g	microgram

μl	microliter
K_I	inhibition constant
k_2	rate constant
V_{max}	maximum velocity

I. INTRODUCTION

Arthritis and rheumatism are frequently used words which are often employed without a clear understanding as to their underlying meaning or knowledge of their causes.¹ Arthritis is the general term used when the joint itself is the major site of the rheumatic disease, while rheumatology is the study of the rheumatic diseases, including arthritis, fibrositis, rheumatic fever, bursitis, neuralgia, gout, and other conditions producing stiffness, soreness, or somatic pain.² According to the estimates obtained from numerous surveys, and quoted by the Arthritis Foundation in 1982,³ there are more than 36,000,000 persons in the United States suffering from some sort of arthritis or related disease.

Rheumatoid arthritis is one of the most prevalent types of rheumatic disease and has received increasing interest by various disciplines within the scientific community. It is relatively common, and in its more serious forms it can lead to severe crippling and disability. The origin of rheumatoid arthritis has eluded detection despite a great expenditure of resources and energy. It appears that the pathology of rheumatoid arthritis is undoubtedly related to an

inflammatory response involving the immune system, and the initiating event which triggers this response is most likely a specific etiologic agent.²

Recently, the interest of most workers have focused on immunologic phenomena as the instigators of the primary pathogenetic mechanisms in the causality of rheumatoid arthritis.⁴⁻⁶ The most common way to account for inflammation in a rheumatoid joint, in the absence of any known etiologic agent, is to invoke an altered immune reaction. There is evidence to suggest that immunologic events occur in rheumatoid arthritis, particularly in the joints. Rheumatoid factors have been observed with rheumatoid arthritis. Immune complexes formed between rheumatoid factors and γ globulin are phagocytized by leukocytes in vitro⁷ or in the synovial fluid in the joint.⁸ As a result of phagocytosis of particulate complexes, leukocytes may degranulate⁹ releasing their lysosomal and hydrolytic enzymes into the joint fluid, possibly provoking local inflammation.

Analysis of synovial fluid plays a major role in the diagnosis of joint disease. Synovial fluid is basically an ultrafiltrate of the plasma combined with a mucopolysaccharide (hyaluronate) that is synthesized by the cells of the synovial membrane.¹⁰ The functions of the synovial fluid are to lubricate the joint space and transport nutrients to the articular cartilage.¹¹

Destruction of the synovial fluid with age or in a disease state may lead to the development of degenerative joint disease (osteoarthritis). Inflammatory joint fluids contain lytic enzymes that produce depolymerization of hyaluronic acid greatly impairing the lubricating ability of the fluid.¹¹

Every year additional enzymes have been found in elevated concentrations in rheumatoid joint effusions leading to an already impressive list. Examples illustrating the diversity of these enzymes are given in Table 1.

There is indirect evidence to support the idea that the enzymes are not circulatory since their activities in the sera of rheumatoid patients are found to be within normal limits.^{25,26} It has been shown in inflammatory diseases that synovial cells,²⁷ leukocytes infiltrating the synovial tissue,¹⁸ and cartilage cells²⁸ are all involved in the increase of the aforementioned enzymes in synovial fluid.

Table 1. Enzymes in Synovial Fluid of Patients with Rheumatoid Arthritis.

Enzyme	Reference
Lactate dehydrogenase	(EC 1.1.1.27) 12
Pyruvate kinase	(EC 2.7.1.40) 12
Aspartate aminotransferase	(EC 2.6.1.1) 12
5'-Nucleotidase	(EC 3.1.3.5) 13
Leucine aminopeptidase	(EC 3.4.11.1) 13, 14
Pepsin	(EC 3.4.23.1) 15
Trypsin	(EC 3.4.21.4) 15
Acid phosphatase	(EC 3.1.3.2) 16
Alkaline phosphatase	(EC 3.1.3.1) 17
Cathepsin D	(EC 3.4.23.5) 18
Cathepsin G	(EC 3.4.21.20) 19
Lysozyme	(EC 3.2.1.17) 19
α -Mannosidase	(EC 3.2.1.24) 20
N-Acetyl- β -D-glucosaminidase	(EC 3.2.1.30) 21, 22
β -Glucuronidase	(EC 3.2.1.31) 23
Myeloperoxidase	(EC 1.11.1.7) 19
Collagenase	(EC 3.4.24.3) 24

Swann²⁹ classified, on the basis of their origin, the synovial fluid macromolecular constituents as follows: a) the constituents derived from blood ; b) the substances secreted by the joint tissues; and c) the products that were derived from the catabolism of the joint. Enzymes and regulators of enzymatic activity have been shown to originate from each of these sources. While it is probable that many of the enzymes that are featured predominantly in diseased joints are derived from infiltrating leukocytes,

recent work has made it clear that in some cases they are derived from the non-vascularized intra-articular tissues such as synovium and cartilage.¹⁸

Hyaluronidase, discovered by Duran-Reynals,³⁰ constitutes a family of enzymes. They can be grouped into various types according to their mechanism of action.³¹ Hyaluronoglucosaminidases (EC 3.2.1.35), hyaluronoglucuronidases (EC 3.2.1.36) and hyaluronate lyases (EC 4.2.2.1) comprise several isoenzymes.³² For example, testicular and lysosomal hyaluronidases are both of the aminidase type, but the former has an optimum pH of 6.0 and the latter a pH of 3.5.³³

Hyaluronidases can also be separated into two groups according to their physiological role. They can function in the metabolism of "self" hyaluronic acid, and yet act upon "non-self" substrates. The first group of hyaluronidases comprise the lysosomal and serum hyaluronidases which are characterized by an in vitro narrow acidic pH range of activity. The second group, the testicular, bacterial, and venom hyaluronidases, are enzymes with an in vitro broad pH range of activity whose optimal pH is close to neutrality.³⁴

Hyaluronidases hydrolyse the (β 1-4) glycosidic bonds in a number of different substrates such as hyaluronic acid, chondroitin 4-sulfate and chondroitin 6-sulfate.³⁵

(Figure 1) These substances are essential for maintaining

the integrity of the extracellular fluid matrix. Alteration of their structure and concentration may affect and modulate numerous cell functions, such as, phagocytosis,^{36,37} adhesion,³⁸ mobility,³⁹ proliferation,^{40,41} and differentiation.^{42,43} The hyaluronic acid-hyaluronidase system takes part in the process of dermis permeability,⁴⁴ embryonic development,⁴⁵ tumor development,^{46,47} cellular immune response,^{48,49} and in the control of the angiogenesis factor.⁵⁰ It also plays an important role in such processes as fertilization,⁵¹⁻⁵³ bacterial infection,⁵⁴⁻⁵⁸ and venom dispersion.⁵⁹⁻⁶²





Figure 1. Action of Hyaluronidase on Different Substrates.

Hyaluronidase in the present study was obtained from human synovial fluid and canine synovial fluid. The properties of this enzyme from different sources have been thoroughly investigated by Meyer, Hoffman and Linker.⁶³ It has been shown that hyaluronidase from rat liver^{64,65} and from fetal rat bone⁶⁶ is localized in the lysosomes of those tissues. The liver enzyme was shown to give an even numbered of oligosaccharide products, which are identical to those produced by the testicular enzyme.⁶⁴ Aronson and Davidson⁶⁷ isolated hyaluronidase from the lysosomes of rat liver. The enzyme was purified 1300 fold by ammonium sulfate precipitation, chromatography on hydroxyapatite and chromatography on Sephadex G-100. The purified fraction gave two peaks, the slower of which yielded a single band using acrylamide gel electrophoresis while the faster of the two was yellow and contained no enzymatic activity. The molecular weight of the slower peak enzyme was calculated to be 89,000 based on sedimentation equilibrium data.⁶⁷

Joy et al³⁵ investigated liver hyaluronidase using pigs as their source of the enzyme. Their technique of purification varied from that of Aronson.⁶⁷ A single band was observed after electrophoresis on polyacrylamide gel yielding an enzyme with an apparent molecular weight of 70,000 and an isoelectric point of 5.0. The substrate specificity of this enzyme was the same as that for bovine testicular hyaluronidase ; however, the K_m and V_{max} values

of the porcine liver enzyme were significantly lower for all substrates (hyaluronate, chondroitin 4-sulfate, chondroitin 6-sulfate).³⁵ The amino acid composition of hyaluronidase isolated from bee venom by Kenemy⁶⁹ is illustrated in Table 2.

Table 2. The Amino Acid Composition of Purified Bee Venom Hyaluronidase

Amino acid	Amount in hyaluronidase found		Reported (b) unoxidised
	unoxidised(a)	oxidised(a)	
Aspartic acid	15.6	16.6	15.9
Threonine	7.0	5.6	6.9
Serine	6.7	6.6	8.6
Glutamic acid	16.2	15.4	11.9
Proline	10.0	9.7	5.3
Glycine	10.1	9.7	8.2
Alanine	9.4	9.4	7.1
Valine	4.2	4.1	6.1
Methionine	0.6	----	1.96
Methionine sulfone	----	1.3	----
Isoleucine	2.8	2.9	4.0
Leucine	10.0	10.0	10.0
Tyrosine	5.7	----	6.5
Phenylalanine	5.7	----	5.0
Lysine	6.9	7.1	9.1
Histidine	1.3	2.0	2.8
Arginine	8.7	8.8	7.8
Half-cysteine	----	----	1.89
Cysteic acid	----	1.1	----

The results obtained on an LKB 4400 automatic amino acid analyser are expressed as a molar ratio, taking leucine as 10.

(a) Results reported by Kemeny⁶⁸

(b) Results reported by King.⁶⁹

The precise role and specificity of hyaluronidase from different sources has yet to be demonstrated. Stephens et al,⁷⁰ compared the properties of human synovial fluid and serum hyaluronidase in an attempt to elucidate the origin of this enzyme and explain the lack of correlation of the enzyme activity with inflammatory indices. Bovine testicular hyaluronidase which has been used by many workers as a model system for examining the effects of drugs and other agents on human hyaluronidase has also been investigated for its properties.⁷¹⁻⁷³

Purification of the human synovial enzyme was accomplished by ammonium sulfate fractionation, agarose gel permeation chromatography and hydroxylapatite gel chromatography. Serum and synovial fluid enzymes gave essentially the same pH-activity relationship and behaved as typical lysosomes. Their pH optimum was approximately 3.4 with no activity produced above pH 5.0 while bovine testicular hyaluronidase had optimal activity at pH 5.0 and very low activity at pH 3.4.⁷⁰

According to Stephens et al,⁷⁴ in contrast to the findings dealing with exopolysaccharides, the hyaluronidase activity in fluids obtained from the pathological groups consisting of rheumatoid and osteoarthritic patients were found to be similar. The hyaluronidase activity levels of both the rheumatic and osteoarthritic samples were always less than that for normal serum. Hyaluronidase in synovial

fluid does not appear to be a product of inflammatory cells within the joint. In view of its low molecular weight estimated to be 60,000 by column chromatography, it is likely that the enzyme may be derived from a remote source such as diffusion from serum.⁷⁴ Serum hyaluronidase is indeed very similar⁷⁵ in properties to the synovial fluid enzyme and is known to be inhibited in the same manner as the serum enzyme by a substrate universally present in mammalian blood.⁷⁶

This result, coupled with the requirements for acidic conditions makes it unlikely that the 3-enzyme system (Figure 2)⁷⁴ is active in synovial fluid in vivo. Rather, the lysosomal environment within phagocytic cells would appear as the most favorable one for glycosaminoglycan catabolism by the mechanism outlined.⁷⁴

Different types of drugs have been used in controlling the symptoms of rheumatoid arthritis with no one drug leading to a complete cure. There is a wide and unpredictable variation of patient response to the different drugs. At the present time, non-steroidal anti-inflammatory drugs and slow acting anti-rheumatic drugs are being used to treat the disease.

ENZYME DEGRADATION OF HYALURONATE




Figure 2. Scheme for the Mechanism of Total Degradation of Hyaluronate by Rheumatoid Synovial Fluid. High molecular weight substrate is first cleaved by hyaluronidase, and the oligosaccharides produced are further attacked by exopolysaccharidases.

Among rheumatologists in the United States, gold is currently the most popular long-term suppressive drug for the treatment of rheumatoid arthritis,⁷⁷ and it has been used successfully for the past sixty years. Gold is available in parenteral as well as oral form.⁷⁸ During parenteral administration, gold binds to albumin, and then tends to concentrate in the liver, kidney, spleen and lymph nodes.⁷⁹ Gold also concentrates in synovial tissues but not in cartilage. Autoradiography has shown increased concentrations of gold in subsynovial membranes in the area of perivascular infiltration of mononuclear cells.⁸⁰ Myochrysine (gold sodium thiomalate) and Solganal (aurothioglucose) are the preparations of choice for parenteral use.⁷⁷

The exact mechanism of gold action is unknown. Besides antibacterial properties, gold exhibits partial suppressive phagocytic activity on macrophages and neutrophils. Gold stabilizes lysosomal membranes, thus inhibiting enzyme release. Most investigators, in recent years, suggest both an immunostimulative and an immunosuppressive effect of gold; thus, it may be an immunoregulating agent.⁸¹ Biggs et al⁸² recently demonstrated that all parenteral gold compounds, that is, gold sodium thiomalate, aurothioglucose, and sodium aurothiosulfate, (Figure 3) bind to the serum proteins at the same rate and exhibit similar affinity constants and labelling capabilities. The mechanism of this

reaction is not well understood, but it is likely to involve the well-recognized property of the gold compounds' ability to interact avidly with the sulfhydryl side chains of proteins.^{83,84} Lorber et al⁸⁵ reported that gold shows a concentration-dependent affinity for other serum compounds including immunoglobulins and complement. Finally, injectable gold shows affinity for other circulating elements of the blood including erythrocytes⁸⁶ and lymphocytes.⁸⁷


Auranofin is a synthetic gold compound in which the central atom of gold is stabilized by covalent bonding with two side groups, a phosphine ligand and a sulfur ligand.⁸⁸ Unlike parenteral gold, Auranofin exhibits cellular-binding rather than almost exclusively binding to serum proteins. From recent studies, it was demonstrated that 40% to 66% of intramuscular gold is associated with cells,⁸⁹⁻⁹¹ primarily erythrocytes following oral administration. The balance was found to be largely bound to albumin. Cell specific binding might possibly represent part of a biologic reservoir or transport system as discussed by Stephens.⁶⁷

Auranofin has proven to be quite effective in reducing carrageenan-induced edema in a model of inflammation as shown in the studies by Walz et al.⁹² Inhibition of edema formation of 62% to 80% were obtained with varying doses of the drug. In contrast, gold sodium thiomalate and gold

sodium thioglucose did not significantly inhibit the rat paw formation edema.

Corticosteroids have played a prominent role in the therapy of rheumatic diseases since their discovery in the late 1940s. The various metabolic, anti-inflammatory, and immunosuppressive effects of the corticosteroids are the result of a common mode of action on the cells involved in rheumatoid inflammation.⁹³ Some steroids are known to inhibit the production of proteinases such as collagenases and plasminogen activator by synovial cells and macrophages.⁹⁴⁻⁹⁶

In an active site-directed mechanism, the enzyme binds with the inhibitor in forming a non-covalent complex prior to forming a covalent enzyme-inhibitor complex.⁹⁷ Kitz and Wilson⁹⁸ derived an equation that is based on the appropriate assumption that the enzyme is a reagent, as contrasted to the less rigorous assumption of steady state.⁹⁹ In affinity labeling,



$$K_I = k_2 / k_1 \quad (2)$$

it is assumed that formation of the reversible complex ($E \cdot I$) is in rapid equilibrium compared to the formation of the irreversibly inactivated enzyme ($E \cdot X$) that $(I) \gg (E)$;

and that when the reaction mixture is assayed for enzymatic activity, E and E * I produce full activity while E - X is inactive. Then

$$d [E-X] / dt = k_3 [E*I] \quad (3)$$

$$K_I = [E] [I] / [E*I] \quad (4)$$

$$[E]_T = [E] + [E*I] + [E-X] \quad (5)$$

$$[E]_T = [E*I] K_I / [I] + [E*I] + [E-X] \quad (6)$$

$$d[E-X] / dt = k_3 ([E]_T - [E-X] / (1 + K_I/[I])) \quad (7)$$

$$d[E-X] / [E]_T - [E-X] = k_3 dt / (1 + K_I/[I]) \quad (8)$$

Integrating,


$$\ln([E]_T - [E-X]) = -k_3 t / (1 + K_I/[I]) + \ln [E]_T \quad (9)$$

If the logarithm of enzymatic activity $[E]_T - [E-X] = [E] + [E*I]$ is plotted against time, the observed first order rate constants, k_{obs} , may be calculated from the slope or by $k_{obs} = 0.693/t_{1/2}$ and is related to the desired constants by equation 10.


$$k_{obs} = k_3 [I] / (K_I + [I]) \quad (10)$$

Since this equation predicts hyperbolic saturation kinetics, a plot of $1/k_{\text{obs}}$ versus $1/[I]$ allows a graphical estimation of k_3 and K_I .


The purpose of this investigation was to isolate, purify, and partially characterize the enzyme hyaluronidase and then study the inhibition of the enzyme with a gold complex, Auranofin and compare it with a well known steroid, anti-inflammatory drug, 22-ketocholesterol oxime.




THIOGLUCOSAURATE (I)
SOLGANOL



SODIUM THIOMALATOAUATE (I)
MYOCHRYNIN



S-2,3,4,6-TETRAACETYL- β -D
THIOGLUCOSYL-(TRIETHYLPHOSPHINE)
AUATE (I)
(AURANOFIN)



SODIUM BIS(THIOSULFATO-S)
AUATE (I)
(SANOCHRYNIN)

Figure 3. Gold Complexes Used in the Treatment of Rheumatoid Arthritis.

II. EXPERIMENTAL

Materials

The following materials were used.

Sigma Chemical Co.

Ammonium persulfate
Bovine serum albumin
p-Dimethylaminobenzaldehyde
Hyaluronic acid
Hyaluronidase
Potassium tetraborate
Sephadex G-75
N,N,N',N',-Tetramethylethylenediamine
Trizma 7-9

J.T. Baker Chemical Co.

Hydrochloric acid

Calbiochem-Behring Corp.

Hydroxylapatite

Florida Distiller Co

Absolute ethanol

Eastman Kodak Co.

Coomassie Blue R-250
N,N', methylene-bisacrylamide
Photo-flo 200 solution

Smith Kline & French Laboratories.

Auranofin

Dr. Edward Parish.

22-ketocholesterol oxime

Allied Chemical

Bromophenol Blue

Fisher Scientific Co.

Acetic acid
Acrylamide
Formic acid
Sodium acetate
Sodium chloride
Sodium hydroxide
Sodium phosphate monobasic
Trichloroacetic acid
Sucrose

Apparatus

- | | |
|---|-------------------------------|
| 1. Electrophoresis apparatus
for slab gels | Hoefer Scientific Instr. |
| 2. Mettler balance | Mettler Instrument Corp. |
| 3. Uv/Vis Spectrophotometer
Model no. 250 | Gilford Instrument |
| 4. Laboratory oven | Grieve-Hendry Co. Inc. |
| 5. Fraction collector | Isco Inc. |
| 6. Superspeed RC2-B
Automatic refrigerated
centrifuge | Sorvall Co. |
| 7. pH-meter | Radiometer-Corporation |
| 8. Incubator | Precision Scientific
Corp. |
| 9. Hot-plate/Stirrer | Corning Glass Work |
| 10. Pipetman | Rainin Instrument Co. |
| 11. Chromatography
Column | Glenco Scientific Inc. |

Sample Preparation

Human synovial fluids were obtained from the Hughston Sports Medicine Hospital and the Medical Center, Doctor's Hospital in Columbus, Georgia and the Internal Clinical Laboratories in Atlanta, Georgia. Animals under investigation at the Small Animal Clinic, College of Veterinary Medicine, Auburn University, Auburn, Alabama were the source of canine synovial fluid.

Stored, frozen synovial fluid samples were thawed and centrifuged at $9,000 \times g$ at 4°C in a refrigerated centrifuge to remove cellular debris. The supernatant was collected and stored at -20°C for further experimentation.

Hyaluronidase Activity

Hyaluronidase was assayed by a modification of the method of Reisse, Strominger, and Leloir.¹⁰⁰ The substrate stock solution of hyaluronic acid was 1.25 mg/ml and it was prepared by dissolving 20 mg of the hyaluronic acid in 16 ml of distilled water. Two hundred fifty μl of the 1.25 mg/ml substrate solution was mixed with 250 μl of 0.2 M formate buffer at pH 4.0 and 25 μl of the enzyme solution. The prepared samples were then incubated at 37°C for twenty hours. One hundred μl of 0.8 M potassium tetraborate was added to each assay tube and heated in vigorously boiling water for three minutes and cooled in tap water. Three ml of dimethylaminobezaldehyde reagent were added and after

mixing, the tubes were heated for twenty minutes at 37°C. The tubes are then cooled, and the amount of N-acetylglucosamine groups released were measured at 585 nm. To calculate the concentration of the product N-acetylglucosamine, the gram molecular weight was taken to be 221.2.

Protein Concentration and Specific Activity

The protein concentration was determined using the Bradford protein assay. This method was based on the observation that the maximum absorbance for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465nm to 595 nm when binding to proteins.^{101,102} The Bradford protein assay is commercially available as a kit from Biorad; containing lyophilized protein (bovine serum albumin) and a dye reagent provided as a five-fold concentrate. The dye was diluted, four parts distilled water to one part dye, and then filtered through Whatman number one filter paper. The standard assay contained 5-500 µg of protein. The absorbance was measured on the spectrophotometer at 595 nm at 25°C. Specific activity was defined as the µmol/min/mg of protein at 25°C.

Purification of Hyaluronidase

Human synovial fluid collected from different patients were pooled and stored for further use. The pooled portions were diluted 1:1 volumetrically with ice cold buffer

containing 0.1 M acetic acid, 20% sucrose, 1.0 mM EDTA and 0.01% Triton X-100 at pH 5.0. A Sorvall refrigerated centrifuge with a SS-34 rotor was used to centrifuge the homogenate at 12,000 x g for 40 minutes at 4°C. The supernatant solution was filtered through glass wool to remove any particles floating in solution and then adjusted to pH 5.0 by addition of 0.5 M acetic acid buffer. This solution was utilized for the first step in the purification. Batches of 50-70 ml each were used in the following procedure.

Sephadex G-75-120 Chromotography

The method described by Reiland ¹⁰³ was used to prepare the Sephadex beads. Two liters of distilled water were used to suspend twenty-five grams of Sephadex G-75-120 powder, which was then heated in a water bath at 70°C for three hours and allowed to stand overnight. The supernatant solution was discarded and the remaining slurry was degassed and poured into a 2.5 X 110 cm glass column. A 0.01 M sodium acetate buffer containing 1.0 mM EDTA and 0.1 M NaCl at pH 5.0 and 4°C was used to equilibrate the packed column for 24 hours at which time a flow rate of 30 ml/hr was established. Seventy ml of the supernatant solution from the previous step was applied to the top of the column and the sample was eluted with the same equilibrating buffer at a flow rate of 25 ml/hr. The eluents were collected in 5.0

ml fractions and analyzed first for protein content in the spectrophotometer at 280 nm. The hyaluronidase activity for each protein fraction was measured as previously described. The enzyme fractions were pooled and used in the next purification step.

Hydroxylapatite Chromotography

The active enzyme fraction from the G-75 column was applied to a 1.5 X 4.5 cm column of hydroxylapatite (Calbiochem) which had been equilibrated with 10 mM sodium phosphate buffer containing 1 mM EDTA at pH 7.0 for six hours. The column was eluted with the same equilibrating buffer at a flow rate of 18 ml/hr and then eluted with 200 ml of a 10-250 mM sodium phosphate gradient. One and one-half ml fractions were collected at a flow rate of 18 ml/hr. The fractions were analyzed for protein content and hyaluronidase activity as previously described.

Gel Electrophoresis

Polyacrylamide gel electrophoresis was performed on the samples using slab gels. Theoretically, electrophoresis through polyacrylamide gels should lead to enhanced resolution of a sample compound because the separation is based on both molecular sieving and electrophoretic mobility. Polyacrylamide gels were prepared by the free radical polymerization of acrylamide and the crosslinking agent, N-N'-methylene-bis-acrylamide. Chemical

polymerization is controlled by an initiator/catalyst system, ammonium persulfate, N,N,N',N'-tetramethylethylenediamine (TEMED).¹⁰⁴

The gel stock solutions were prepared according to the method of Davis.¹⁰⁵ The solutions were stored at 4°C for two weeks while the ammonium persulfate was freshly prepared prior to use. Equilibration and degassing of the solutions were completed before polymerization with the catalyst. The glass plates were pretreated with Kodak photo-flo 200 solution prior to usage to enhance evenness of gels.

To perform the polyacrylamide gel electrophoresis the following reagents were prepared.

1. 10% separating gel:

13.5 ml of a 22.6% acrylamide and a 0.6%
N,N'-methylene bis acrylamide solution
15 ml of 0.375 M Tris buffer at pH 8.7
0.025 ml TEMED

2. 3.5% Stacking gel:

34 ml of a 22.6% acrylamide and a 0.6%
N,N'-methylene bis acrylamide solution
34 ml distilled water
7.5 ml of a .0125 M Tris buffer at pH 6.8

3. Catalyst:

A 10% solution of ammonium persulfate was made by dissolving 0.1 g of ammonium persulfate in 1 ml of distilled water.

4. Fixing solution:

10% trichloroacetic acid

5. Stain stock:

Coomassie Blue G-250 solution

6. Sample buffer:

0.08 M Tris at pH 6.8

1 M sucrose

0.01% bromophenol blue (tracking dye)

0.02 M EDTA

7. Stain:

0.05% solution of the stain stock

7% acetic acid

5% methanol

8. Destaining solution:

7% acetic acid

5% ethanol



Procedure for Preparing the Gels

A 10% acrylamide gel was prepared as described earlier. The polymerization was initiated by the addition of the catalyst. After completion of the polymerization, the slab gel was layered with the stacking gel. The protein samples were diluted 1:1 with the sample buffer and electrophoresis was allowed to proceed for six hours at 8 ma/slab gel. The proteins were located using the Coomassie Blue G-250 stain which was added to the gels with the protein samples. The

gels were placed in the fixing solution for fifteen minutes and then in the staining solution for overnight incubation. The stained gels were washed in the destaining solution for several hours with continuous shaking to destain the gel background. The finished gels were placed in plastic bags containing 7% acetic acid and stored at 37°C.

Inhibition studies

Hyaluronidase was tested for inhibition with a gold compound, Auranofin and a steroid, 22-ketocholesterol oxime.




Hyaluronic acid was used as the substrate for the studies. Both the steroid and gold complex were first dissolved in absolute ethanol and further diluted in a 0.2 M phosphate buffer, pH 4.0 because of their insolubility in aqueous media. A constant concentration of enzyme (0.1 mg/ml) was mixed with different gold and steroid concentrations. The concentrations of Auranofin were varied from 1.0 mM to 10 mM. Fifty μ l aliquots of gold complex-enzyme mixture were tested over a period of twenty-four hours for enzyme activity. The steroid concentrations were varied from

1.25 mM to 7.5 mM. The steroid enzyme-inhibitor mixtures were tested according to the procedure followed for Auranofin. Control experiments were conducted in the same buffer-ethanol mixtures. The control involved the use of the enzyme hyaluronidase without an inhibitory compound.

III. RESULTS

Enzyme Analysis of Synovial Fluid

The hyaluronate digestion catalyzed by the enzyme hyaluronidase is shown in the following equations.



As the enzyme catalyses the cleavage of the acetal bonds, N-acetylglucosamine end groups are formed and measured as described in the assay procedures. The activity was recorded as absorbance/hr and then converted to $\mu\text{mol}/\text{min}$ of N-acetylglucosamine using the standard curve (Figure 4). The protein concentration was measured using the Bradford protein assay kit. The absorbance of protein was then converted to mg of protein by using the BSA standard curve shown in Figure 5. The specific activity of the enzyme was then determined in the units $\mu\text{mol}/\text{min}/\text{mg}$ protein.




Figure 4. Standard Curve of Absorbance Versus Concentration of Acetylglucosamine.




Figure 5. Standard Curve of Absorbance Versus Concentration of Bovine Serum Albumin.

Canine Synovial Fluid

The hyaluronidase activity in unpurified canine synovial fluid from 13 dogs was determined and the tabulated activities are shown in Table 3. A thirteen-fold increase was observed in the activity of the 4 rheumatic dogs as compared to the 7 normal dogs. In addition, 2 synovial samples tainted with blood contained approximately 40 fold greater hyaluronidase activity than normal synovial fluid and three times greater activity than fluid from rheumatic dogs.

Table 3. Comparison of Mean Hyaluronidase Activities in Canines

Condition	Number of Subjects	Mean $\times 10^3$ Units/ ml synovial fluid
Rheumatoid	4	1.97 $\pm$.24
Normal	7	0.15 $\pm$.05
Blood tainted Synovial Fluid	2	6.02 $\pm$.38

*Unit = μ mole/min

Human Synovial Fluid

The purification of human synovial hyaluronidase by gel filtration thru Sephadex G-75-120 is illustrated in Figure 6. When measured at 280 nm, the elution profile revealed 3 protein peaks but only one peak contained activity. Peaks A & B showed no hyaluronidase activity while peak C (tubes 80-125) contained the hyaluronidase activity of

0.49×10^{-4} units/mg. One peak containing catalytic activity was obtained from the hydroxylapatite chromatography of the G-75-120 preparation. The elution profile is shown in Figure 7. The single peak yielded a specific activity of 1.1×10^{-4} units/mg which represents a four fold increase in specific activity. Table 4

Table 4. Purification Procedure for Human Synovial Fluid Hyaluronidase

Step	Activity (μ moles/min/ml)	Protein (mg/ml)	Specific Activity $\times 10^3$ (μ mole/min/mg)
Homogenate (10,000 x g)	0.000866	32.1	0.028
G-75-120	0.00076	15.5	0.049
Hydroxylapatite	0.000376	3.4	0.11

Gel Electrophoresis

Polyacrylamide gel electrophoresis was performed after purification to determine the purity of the enzyme. The protein bands were identified by staining the gels in a solution of Commassie Brilliant Blue, a dye which preferentially binds to proteins (Figure 8). From the polyacrylamide gel electrophoresis, a single band of the purified hyaluronidase was obtained (Figure 9). Using a series of proteins as molecular weight standards, a purified sample of hyaluronidase was estimated to have a molecular weight of 48,000.




Figure 6. Chromatography of Human Synovial Fluid Hyaluronidase on Sephadex G-75-120 Column. The supernatant from step 1 was applied onto a 2.5 x 110 cm column and eluted with 0.01 M acetate buffer containing 0.01% triton X-100, 1.0 mM EDTA, at pH 5.0.
 X----X, Enzyme activity; +---+, Protein profile




Figure 7. Chromatography of Human Synovial Fluid Hyaluronidase on Hydroxylapatite. The dialysate from step 2 was applied onto a 1.5 x 4.5 cm column, previously equilibrated with the dialysis buffer, 10 mM sodium phosphate, 1 mM EDTA at pH 7.0. The enzyme was eluted with 200 ml of a linear gradient (10-250 mM) sodium phosphate. X---X, Enzyme activity; +---+, Protein profile.

Enzyme Inhibition

Hyaluronidase from human synovial fluid was inhibited by the gold complex Auranofin. The rate of inactivation is shown in Figures 10. A slow and gradual loss of enzyme activity was observed over a period of 24 hours. The control uninhibited hyaluronidase did lose 3% activity within 24 hours, however, the other curves have been corrected for the loss.


With the use of the semilog plot of remaining activity, a linear relationship was developed to an inactivation level of 45% as seen in Figures 10 & 11. Using the double reciprocal plot (Figure 12), Auranofin yielded a K_I of 8.78 mM and a k_3 of 0.049 min^{-1} .

The steroid derivative, 22-ketocholesterol oxime, was analyzed for inhibition and kinetics. The rate of inactivation is shown in Figure 13. It was observed that 22-ketocholesterol oxime induced an inhibition of enzyme activity which plateaued by six hours. A semi-log plot of data in Figure 13 did not yield straight lines indicating the absence of the irreversible step leading to formation of the covalently bonded E-X complex (Figure 14). A Lineweaver-Burk plot of the steroid induced inhibition yielded parallel straight lines thereby suggesting an uncompetitive inhibition behavior (Figure 15).



1. Osteoarthritis (Human)
2. Rheumatoid Arthritis (Human)
3. Rheumatoid Arthritis (Canine)
4. Normal (Canine)

Figure 8. Protein Staining of the Gel Electrophoresis for Human Versus Canine Synovial Fluid.



1. Hydroxylapatite Peak
2. Sephadex G-75-120 Peak C
3. Protein Standards

Figure 9. Protein Identification Bands of Hyaluronidase Purification with Protein Standards.




Figure 10. Time Course Inactivation of Hyaluronidase by Auranofin.




Figure 11. Semilog Plot of Data From Figure 10 Against Inactivation Time by Auranofin.




Figure 12. Reciprocal Plot of Pseudo First Order Rate Constant with the Auranofin Concentration.




Figure 13. Time Course Inactivation of Hyaluronidase by 22-Ketocholesterol Oxime.




Figure 14. Semilog Plot of Data From Figure 13 Against Inactivation Time by 22-Ketocholesterol Oxime.




Figure 15. Lineweaver-Burk Plot of the Inhibition of Hyaluronidase by 22-Ketocholesterol Oxime.

Secondary plots of the reciprocals of $V_{\max_i}$ against the [I] concentrations gave straight line curves best fitted in the following equation.¹⁰⁶

$$1/V_{\max_i} = 1/V_{\max} K_I [I] + 1/V_{\max} \quad (12)$$

The kinetic constants for the inhibition of hyaluronidase by 22-ketocholesterol oxime evaluated directly from Figure 16 were 11.86 mM and 30.3 $\mu\text{mole/min}$ for K_I and $V_{\max}$, respectively.




Figure 16. Secondary Plot Computed from the Lineweaver-Burk Curves in Figure 15.

IV. CONCLUSION

Hyaluronidase was purified from human synovial fluid following a modified procedure based on the work of Aronson and Davidson ⁶⁷. Using the modified procedure, human synovial fluid produced relatively smaller quantities of active enzyme. Upon completion of the purification, a specific activity of 1.1×10^{-4} $\mu\text{mole/min/mg}$ was obtained which corresponds to a 4-fold increase in purification. Comparison of the specific activity of hyaluronidase from human synovial fluid characterized in the present study with hyaluronidase isolated from rat liver, honey bee venom, and pig liver is difficult due to the different assay procedures. The marked difference in assay conditions of Joy et al ³⁵ (0.1 M sodium citrate buffer, pH 4.5, 0.15 M NaCl) for pig liver and of Kemeny et al ⁶⁸ (0.1 M sodium acetate buffer, pH 6.0, 0.15 M NaCl) for honey bee venom versus those used in the present study (0.2 M sodium phosphate buffer, pH 4.0) preclude a direct comparison of enzyme activity.

The G-75-120 chromatography produced three separate peaks; the first two with no enzyme activity while the third peak contained the enzymatic activity. On elution through the hydroxylapatite column, one enzyme peak was produced which corresponds to previous studies. As reported by

Aronson and Davidson,⁶⁷ the purification procedure through the hydroxylapatite column allowed enhanced purification during each experiment but the loss of the enzyme varied from 30% to 75%.

The purified hyaluronidase was quite stable during the assay procedures using a 0.2 M formate buffer, pH 4.0. After the required twenty hour incubation time, the enzyme had no notable loss of activity. Polyacrylamide gel electrophoresis of the purified enzyme yielded only one major band as seen in Figure 8.

A separate study was conducted to compare the profile of hyaluronidase in human versus canine synovial fluid. The gel electrophoresis patterns, Figure 9, produced common protein bands from both human and canine synovial fluid samples. As seen in previous studies,¹⁰⁷ from our laboratory, it has been demonstrated that the acid phosphatase enzyme activity levels in human synovial fluid are higher in rheumatic synovial fluid as compared to normal fluid. The findings of the present study showed a thirteen fold increase in hyaluronidase activity from the synovial fluid of rheumatic dogs as compared to the non-rheumatic control dogs. (Table 3).

The levels of hyaluronidase in rheumatoid synovial fluids of humans do not significantly differ from those of osteoarthritic fluids.⁷⁴ It has been suggested that the enzyme is not produced locally in the joint by inflammatory

synovial cells.⁷⁴ In a comparative study, two samples of canine synovial fluid tainted with blood produced hyaluronidase levels three to forty times the amount seen in corresponding synovial samples (Table 3). With a determined molecular weight of 48,000 for human synovial fluid hyaluronidase as compared to 45,000 for serum albumin, it is possible that both canine and human synovial fluid hyaluronidase are derived by diffusion from the blood as discussed by Stephens, et al.⁷⁴

After purification, the inhibition of hyaluronidase by a gold complex, Auranofin, and a steroid derivative, 22-ketocholesterol oxime, was investigated. Both compounds had inhibitory effects on the enzyme. Auranofin caused a steady decrease of hyaluronidase activity over the twenty-four hour period as seen in Figure 10. The initial rate constants were calculated from the reciprocal plot (Figure 12). As outlined in the previous section (eq.2), the evaluation of K_I is dependent on the formation of the reversible complex ($E \cdot I$) which is in equilibrium with the free enzyme, and then reacts slowly to form the stable covalently bonded $E - X$ complex. The rate constant k_3 represents the irreversible activation and this step represents the covalent bonding of the Au to a nucleophile such as S or possibly the N of a histidine, lysine or arginine. Several studies have shown that the above binding is seen in reactions of Pt(II)¹⁰⁸ as well as Au(III)⁹⁷

complexes containing sulfhydryl groups at the active site. Our studies showed that Auranofin had a 10% to 55% inhibitory effect on hyaluronidase activity (Figure 10).

In this study, the steroid exhibited behavior suggestive of a reversible type of association with the enzyme hyaluronidase. Employing an inhibition equilibrium study, we were able to obtain results and calculate associated parameters. As discussed in previous publications from our lab, the mode of inhibition by 22-ketocholesterol oxime may be best explained by the location of the nitrogen atom in the aliphatic hydrocarbon chain of the steroid derivative since the rest of the molecule is unreactive. The actual role of the nitrogen atom has yet been determined.¹⁰⁷

The results of the present studies show a definite difference between the inhibition by the gold complex versus the steroid derivative. Auranofin probably has an intermolecular interaction with the enzyme due to the formation of the covalent complex E - X rather than the weak association complex. This can be supported by the high K_I value of 8.78 mM and the relatively small rate constant of 0.05 min^{-1} . The small rate constant may represent the long time requirement exhibited by the gold complex to elicit the permanent inhibitory effects. The steroid derivative had a K_I of 11.86 mM and showed formation of a reversible equilibrium complex. As other studies have shown, steroids

elicit temporary relief in inflammation with the possibility of forming an equilibrium complex.

The results obtained in the present study dealing with Auranofin and 22-ketocholesterol oxime are similar to those obtained by Haddad¹⁰⁷ in our laboratory. She evaluated the kinetics of Auranofin-induced inhibition of acid phosphatase obtained from human synovial fluid. She showed Auranofin inhibited acid phosphatase with a K_I of 0.545 mM and a k_3 of 22.7 min^{-1} . Since both studies show weak inhibitor-enzyme association as illustrated by similar K_I values and slow rates of covalent bond formation as illustrated by similar k_3 values for Auranofin, it is suggestive that the interaction between the enzyme and gold complex is more likely to involve a weak nucleophile such as nitrogen rather than a sulfhydryl group or at least not a fully accessible sulfhydryl group as is expected for stronger gold-enzyme interactions. However, these observations need to be tested by further experimentation. When comparing the K_I 's of the steroid derivative with the gold complex (as calculated from the Lineweaver-Burk plots Figure 12 & 16), the similarity in the values with the findings of Haddad¹⁰⁷ suggest a similar bonding profile. It is possible that both inhibitory complexes initially associate with the same groups on the enzyme or by a similar mechanism. However, the specific mechanisms of intermolecular interactions must be shown by further experimentation. After both inhibitors form the

initial equilibrium association for a period of time, the gold eventually forms a stable complex with a strong bond while the steroid is released. It is hard to assess what role the geometry of the molecules might have but may be reflected in the observed differences.

Therefore, it can be concluded that both the gold complex and the steroid derivative are inhibitors of hyaluronidase. With the use of a suitable test model and further experimentation, it may be possible to elucidate the molecular interactions of various anti-inflammatory drugs.

REFERENCES

1. Scott, J.T., in "Arthritis and Rheumatism, the Facts", Oxford University Press., New York., 1980, 1-25
2. McCarty, D.J. Jr., in "Arthritis and Allied Conditions", 10th ed., Lea & Febiger, Philadelphia, Penn., 1985, 3-15
3. Arthritis Foundation:Annual Report. Atlanta, 1982, 1-36
4. Kunkel, H.G., Fed. Proc., 1964, 23, 623-626
5. Vaughan, J.H.; Barnett, E.V., and Leddy, J.P., New Eng. J. Med., 1966, 275, 1426-1432
6. Ziff, M., Ann. Rheum. Dis., 1965, 24, 103
7. Parker, R.L., and Schmid, F.R., J. Immunol., 1962, 88, 519
8. Hollander, J.L.; McCarty, D.J. Jr.; Astorga, G., and Castro-Murillo, E., Ann. Int. Med., 1965, 62, 271
9. Zucker-Franklin, D., and Hirsch, J.G., J. Exper. Med., 1964, 120, 569-575
10. Currey, H.L.F., and Roberts, B.V., Clin. Rheum. Dis., 1976, 2, 149-176
11. Kjeldsberg, C.R., and Knight, J.A., in "Body Fluids", 2nd ed., American Society of Clinical Pathologists Press, Chicago, Ill., 1972, 129-152
12. Kerby, G.P., and Taylor, S.M., Proc. Soc. Exp. Biol. Med., 1967, 126, 865-868
13. Takala, I.; Makisara, P.; and Kulonen, E., Scand. J. Rheumatol., 1977, 6, 33-36
14. Michajlik, A., and Gietka, J., Abstr. VII Eur. Rheum. Congr., 1971, 16, 11
15. Vartio, T., Ann. Med. Exp. Fenn., 1960, 38, 94-99

16. Beckman, G.; Beckman, L., and Lemberg, R., Acta. Rheumatol. Scand., 1971, 17, 47-56
17. Mach, P.S.; Auscher, C.; Kahan, A.; LeGo, A., and Delbarre, F., Biomedicine, 1974, 20, 61-67
18. Peltonen, L.; Puranen, J.; Lehtinen, K., and Korhonen, L.K., Scand. J. Rheumatol., 1981, 10, 107-114
19. Hadler, N.M.; Spitznagel, J.K., and Quinet, R.J., J. Immunol., 1979, 123, 572-577
20. Pugh, D., and Walker, P.G., J. Histochem. Cytochem., 1961, 9, 242-250
21. Bartholomev, B.A., and Perry, A.L., Acta. Rheum. Scand., 1970, 16, 304-310.
22. Muirden, K.D., and Mills, K., Abstr. VII Eur. Rheum. Congr., 16.10, 1971.
23. Jacox, R.F., and Feldmahn, A., J. Clin. Invest., 1955, 34, 263-267
24. Wooley, D.E.; Crossley, M.J., and Evanson, J.M., Arth. Rheum., 1977, 20, 1231-1239
25. Vanha-Perttula, T., Biochim. Biophys. Acta., 1970, 227, 390-401.
26. Kalliomaki, J.L., and Vanha-Perttula, T., Scand. J. Rheumatol., 1972, 1, 21-26
27. Muirden, K.D. Ann. Rheum. Dis., 1972, 31, 265-271
28. Woessner, J.F. Jr., Fed. Proc., 1973, 32, 1485-1488
29. Swann, D.A., in "The Joints and Synovial Fluid, Macromolecules of Synovial Fluid", Scholoff, L. (ed), Volume 1, Academic Press., N.Y., 1981, 407-435
30. Duran Reynals, F., C. R. Soc. Biol., 1928, 99, 6-7
31. IUPAC-IUB Commission on Biochemical Nomenclature Enzyme Nomenclature 1978., Academic Press., 1979, N.Y.
32. IUPAC-IUB Commission on Biochemical Nomenclature., J. Biol. Chem., 1977, 252, 5939-5941

33. Aronson, N.N. Jr., and Davidson, E.A., J. Biol. Chem., 1967, 242, 441-444
34. Fiszer-Szafarz, B., Anal. Biochem., 1984, 143, 76-81
35. Joy, M.B.; Dodgson, K.S.; Olavesen, A.H., and Gacesa, P., Biochim. et Biophys. Acta, 1985, 838, 257-263
36. Goggins, J.F.; Lazarus, G.S., and Fullmer, H.M., J. Histochem. Cytochem., 1968, 16, 688-692
37. Forrester, J.V., and Balazs, E.A., Immunology, 1980, 40, 435-446
38. Barnhart, B.J.; Cox, S.H., and Kraemer, P.M., Exp. Cell Res., 1979, 119, 327-332
39. Hakansson, L.; Hallgren, R., and Venge, P., J. Clin. Invest., 1980, 66, 298-305
40. Balazs, A., and Holmgren, H.J., Exp. Cell Res., 1950, 1, 206-216
41. Fiszer-Szafarz, B., and Nadal, C., Cancer Res., 1977, 37, 354-357
42. Hamasima, N., Dev. Growth Differ., 1982, 24, 353-357
43. Belsky, E., and Toole, B.P., Cell Differ., 1983, 12, 61-66
44. Boyland, E., and McClean, D., J. Pathol. Bacteriol., 1935, 41, 553-565
45. Schoenwolf, G.C., and Fisher, M., J. Embryol. Exp. Morphol., 1983, 73, 1-15
46. Fiszer-Szafarz, B., Biol. Cell, 1981, 42, 97-102
47. Kojima, J.; Nakamura, N.; Kanatani, M., and Akiyama, M., Cancer Res., 1982, 42, 2857-2860
48. Chevrier, A.; Girard, N.; Delpech, B., and Gilbert, D., Biomedicine, 1982, 36, 100-103
49. Turley, E.A., Biochem. Biophys. Res. Commun., 1982, 108, 1016-1024
50. Feinberg, R.N., and Beebe, D.C., Science (Washington, D.C.), 1983, 220, 1177-1179

51. McClean, D., and Rowlands, I.W., Nature (London), 1983, 150, 627-628
52. Fekete, E., and Duran Reynals, F., Proc. Soc. Exp. Biol. Med., 1943, 52, 119-121
53. Waibel, R.; Ginsberg, L.C., and Ficsor, G., J. Histochem. Cytochem., 1984, 32, 63-66
54. Abramson, C., Arch. Biochem. Biophys., 1967, 121, 103-106
55. Greiling, H.; Stuhlsatz, H.W.; Eberhard, T., and Eberhard, A., Connect. Tissue Res., 1975, 3, 135-139
56. Ingham, E.; Holland, K.T.; Gowland, G., and Cunliffe, W.J., J. Gen. Microbiol., 1979, 115, 411-418
57. Fitzgerald, T. J., and Gannon, E.M., Canad. J. Microbiol., 1983, 29, 1507-1513
58. Tam, Y.C., and Chan, E.C.S., J. Dent. Res., 1983, 62, 1009-1012
59. Allalouf, D.; Ber, A., and Ishay, J., Comp. Biochem. Physiol., 1972, 43, 119-123
60. Herd, J.K.; Tschida, J., and Motycka, L., Anal. Biochem., 1974, 61, 133-143
61. Owen, M.D., Toxicon, 1983, 21, 171-174
62. Tu, A.T., and Hendon, R.R., Comp. Biochem. Physiol., 1983, 76, 377-383
63. Meyer, K.; Hoffman, P., and Linker, A., in "The Enzymes", vol. 4", Boyer, P.D.; Lardy, H., and Myrbach, K., (eds), Academic Press, N.Y., 1960
64. Aronson, N.N., and Davidson, E.A., J. Biol. Chem., 1965, 240, 3222
65. Hutterer, F., Biochim. Biophys. Acta., 1966, 115, 312-319
66. Vaes, G., and Jacques, P., J. Biochem., 1965, 97, 380
67. Aronson, N.N., and Davidson, E.A., J. Biol. Chem., 1967, 242, 437-440

68. Kemeny, D.M.; Dalton, N.; Lawrence, A.J.; Pearce, F.L., and Vernon, C.A., Eur. J. Biochem., 1984, 139, 217-223
69. King, T.P.; Sobotka, A.K.; Kochoumian, L., and Lichtenstein, L., Arch. Biochem. Biophys., 1976, 172, 661-671
70. Stephens, R.W.; Sutherland, J.; Gosh, P., and Taylor, T.K.F., Biochem. Pharmacol., 1976, 25, 1507-1511
71. Bekemeier, H.; Hirschelmann, R., and Vieweg, M., Pharmazie, 1973, 28, 744-748
72. Matthews, M.B., and Dorfman, A., Physiol. Rev., 1955, 35, 381-402
73. Fiszer-Szafarz, B., Proc. Soc. Exp. Biol. Med., 1968, 129, 300-302
74. Stephens, R.W.; Ghosh, P., and Taylor, T.K.F., Biochim. et Biophys. Acta., 1975, 399, 101-112
75. Bonner, W.M., and Cantey, E.Y., Clin. Chim. Acta., 1966, 13, 746-752
76. Wattenberger, L.W., and Glick, D., Arch. Biochem., 1951, 35, 290-304
77. Sigler, J.W., Am. J. Med., 1983, 75, 55-62
78. Mullin, G.T., Am. J. Med., 1983, 75, 205-217
79. Gottlieb, N.L., J. Rheumatol., 1979, 6(suppl. 5), 2-5
80. Lawrence, J.S., Ann. Rheum. Dis., 1961, 20, 341-351
81. Bluhm, G.B., J. Rheumatol., 1982, 9(suppl. 8), 10-17
82. Biggs, D.F.; Boland, D.M., and Davis, P., J. Rheumatol., 1979, 6(suppl. 5), 68-73
83. Gerber, D.A., J. Pharmacol. Exp. Ther., 1964, 143, 137-140
84. Penneys, N.S.; Ackerman, B., and Gottlieb, N.L., Arch. Dermatol., 1974, 109, 372-376
85. Lorber, A.; Simon, T., and Leeb, J., J. Rheumatol., 1979, 6(suppl. 5), 82-90

86. Smith, P.M.; Smith, E.M., and Gottlieb, N.L., J. Lab. Clin. Med., 1973, 82, 930-936
87. Lorber, A.; Wilcox, S.A.; Vibert, G.J., and Simon, T., J. Rheumatol., 1979, 6(suppl. 5), 31
88. Walz, D.T.; DiMartino, M.J.; Charkin, L.W.; Sutton, B.M., and Misher, A., J. Pharmacol. Exp. Ther., 1976, 197, 142-152
89. Blocka, K.; Droomgoole, S.; Furst, D., and Paulus, H., Arth. Rheum., 1980, 23, 654
90. Walz, D.T.; Griswold, D.E.; DiMartino, M.J., and Bumbier, E.E., J. Rheumatol., 1979, 6(suppl. 5), 56-60
91. Herrlinger, J.D.; Alsen, C.; Beress R.; Hecker, U., and Weikert, W., J. Rheumatol., 1982, 9(suppl 8), 81-89
92. Walz, D.T.; DiMartino, M.J.; Kuch, J.H., and Zuccarello, W., Proc. Soc. Exp. Biol. Med., 1971, 136, 907-910
93. Rainsford, K.D., in "Anti-inflammatory" and "Anti-Rheumatic Drugs", CRC Press., Florida, 1985, 190-191
94. Dayer, J.M.; Krane, S.N.; Russell, R.G., and Robinson, D.R., Proc. Natn. Acad. Sci. USA, 1976, 73, 945-949
95. Vasslli, J.D.; Hamilton, J., and Reich, E., Cell, 1976, 8, 271-281
96. Werb, Z.; Mainardi, C.L.; Vater, C.A., and Harris, E.D., New Engl. J. Med., 1977, 296, 1017-1023
97. Friedman, M.E.; Chasteen, L.; Shaw, R.; Allen, S., and McAuliffe, C.A., Chem. Biol. Interact., 1982, 42, 321-333
98. Kitz, R., and Wilson, B., J. Biol. Chem., 1962, 237, 3245-3249
99. Cornish-Bowden, A., Eur. J. Biochem., 1979, 93, 383-385
100. Reissig, J.L.; Strominger, J.L., and Leloir, L.F., J. Biol. Chem., 1955, 217, 959-968

101. Bradford, M., Anal. Biochem., 1976, 72, 248-254
102. Spector, T., Anal. Biochem., 1977, 83, 773-777
103. Reiland, J., in "Methods in Enzymology".
Jakoly, W.B., (ed), Vol. XXII, p.287, Academic Press,
N.Y., 1971
104. Boyner, R.F., in "Modern Experimental Biochemistry",
Addison-Wesley Publishing Co., Reading, Mass., 1986,
123-129
105. Davis, B.J., Ann. N.Y. Acad. Sci., 1964, 121, 404-427
106. Segel, I.H., in "Enzyme Kinetics", 2nd. ed., 1975,
John Wiley & Sons Inc., 100-170
107. Haddad, R.S., Ph. D. Dissertation, 1987, Auburn
University, Al.
108. McGuire, J.P., and Friedman, M.E., Inorg. Chim.
Acta., 1984, 91, 161-165

END

DATE

FILMED

6-1988

DTIC